Is Jenburkt Pharma overvalued or undervalued?
As of September 23, 2025, Jenburkt Pharma is fairly valued with a PE Ratio of 14.12 and an EV to EBITDA of 10.87, significantly lower than its peers, indicating strong growth potential despite recent underperformance compared to the Sensex.
As of 23 September 2025, the valuation grade for Jenburkt Pharma has moved from expensive to fair. The company is currently fairly valued based on its financial ratios. Key ratios include a PE Ratio of 14.12, an EV to EBITDA of 10.87, and a PEG Ratio of 0.90, indicating a reasonable valuation relative to its growth prospects.In comparison to its peers, Jenburkt Pharma's PE Ratio is significantly lower than Sun Pharma's 34.11 and Divi's Lab's 69.64, both of which are classified as expensive. Additionally, Jenburkt's EV to EBITDA ratio of 10.87 is more favorable than the industry average, suggesting it is positioned well within the market. Despite recent underperformance compared to the Sensex over the year, the long-term returns of 175.22% over five years highlight its potential for growth.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
